AUTHOR=Jiang Yifan , Zhao Juan , Zhang Li , Tian Sijuan , Yang Ting , Wang Li , Zhao Minyi , Yang Qing , Wang Yaohui , Yang Xiaofeng 

TITLE=Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer

JOURNAL=Frontiers in Oncology

VOLUME=10

YEAR=2020

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00954

DOI=10.3389/fonc.2020.00954

ISSN=2234-943X

ABSTRACT=<p><bold>Purpose:</bold> PARP inhibitors are a novel targeted anti-cancer drug and a large number of clinical studies on PARP inhibitors have been accomplished. This updated meta-analysis was conducted to evaluate the efficacy and safety of PARP inhibitors in advanced-stage epithelial ovarian cancer.</p><p><bold>Methods:</bold> Medline (PubMed), Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus were searched to identify the eligible trials up to April 2020. ClinicalTrials.gov was also screened for additional unpublished trials. Data extraction and risk of bias assessment were performed by two independent investigators, respectively. The hazard ratios (HRs) and its 95% confidence intervals (CI) for time-to-event data of progression-free survival (PFS) and overall survival (OS), and the risk ratios (RRs) with 95% CI for dichotomous data of overall response rate (ORR) and occurrence of adverse events (AEs) were calculated by Review Manager 5.3 and Stata 12.0 software.</p><p><bold>Results:</bold> A total of 12 trials with 5,347 patients were included in this meta-analysis. Compared with the control group, PARP inhibitors significantly improved PFS (HR, 0.51; 95% CI, 0.40–0.65; <italic>P</italic> &lt; 0.00001) and ORR (RR, 1.26; 95% CI, 1.11–1.43; <italic>P</italic> = 0.0003). Specifically, PFS was improved regardless of <italic>BRCA</italic> genes mutations and homologous-recombination status. However, no difference was observed in OS between the PARP inhibitors group and the control group (95% CI, 0.73–1.01; <italic>P</italic> = 0.06). PARP inhibitors were associated with a statistically significant higher risk of hematologic events and different PARP inhibitors had different toxicities profiles.</p><p><bold>Conclusion:</bold> PARP inhibitors are an effective and well-tolerated treatment for patients with advanced-stage epithelial ovarian cancer.</p>